You are here:HomeCorporates

Pfizer mulls buying Strides Arcolab's Agila Specialties - report

Pfizer mulls buying Strides Arcolab's Agila Specialties - report

close

New York:

Pfizer is considering buying India's Agila Specialties, the injectable-medicines unit of Indian drug supplier Strides Arcolab, for a possible price of $2 billion (Rs 10,886.31 crore), Bloomberg reported on Monday.

Pfizer is doing due diligence and a deal could be reached this quarter, Bloomberg reported, citing unnamed sources.

A Pfizer spokeswoman said the company does not comment on market rumours or speculation.

Agila makes cancer treatments and antibiotics, Bloomberg said.

Copyright @ Thomson Reuters 2013

Story first published on: January 15, 2013 10:13 (IST)

Tags: Pfizer, Agila Specialties, Strides Arcolab, India, Cancer, antibiotics


For Profit Update,
Follow NDTV on Pinterest

Social Sharing

Advertisement

Advertisement

Portfolio
 

Advertisement

Market Data provided by © Accord Fintech.
© Copyright NDTV Convergence Limited 2014. All rights reserved.